

Product datasheet for TR309457

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

SH3PXD2B Human shRNA Plasmid Kit (Locus ID 285590)

Product data:

Product Type: shRNA Plasmids

Product Name: SH3PXD2B Human shRNA Plasmid Kit (Locus ID 285590)

Locus ID: 285590

Synonyms: FAD49; FTHS; HOFI; KIAA1295; TKS4; TSK4

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

Components: SH3PXD2B - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID

= 285590). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001017995, NM 001308175, NM 001017995.1, NM 001017995.2, BC016513, BC038561,

BC065230, BC110316, BC156242, BC157116, NM 001017995.3

UniProt ID: A1X283

Summary: This gene encodes an adapter protein that is characterized by a PX domain and four Src


homology 3 domains. The encoded protein is required for podosome formation and is

involved in cell adhesion and migration of numerous cell types. Mutations in this gene are the cause of Frank-ter Haar syndrome (FTHS), and also Borrone Dermato-Cardio-Skeletal (BDCS) syndrome. Alternative splicing of this gene results in multiple transcript variants. [provided by

RefSeq, Apr 2015]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).